Multilateral collaborations will serve to strengthen knowledge sharing to formulate framework for accessible, affordable, and quality healthcare
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
Positive opinions based on significant survival benefit
The approval follows the positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in October 2022
Omicron BA.5 continues to be the most prevalent sublineage in the United States (nearly 30% of cases) at the time of publication of the data
The company registered with REACH Certificate for Ethyl Acetate with a tonnage band of more than 1000 TPA
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
The European Commission will review the CHMP recommendation and is expected to make a final decision soon.
Subscribe To Our Newsletter & Stay Updated
